Table 1.
Characteristics of the total COLIBRI population at the time of data extraction, and comparison between patients with or without complete data
| Characteristics | Total | Complete data | Incomplete data | Overall P Value | |||
|---|---|---|---|---|---|---|---|
| N | Mean ± SD /n (%) | N | Mean ± SD /n (%) | N | Mean ± SD /n (%) | ||
| Age, in year | 4140 | 65.9 ± 9.9 | 1171 | 65.2 ± 8.4 | 2969 | 66.1 ± 10.4 | 0.005* |
| Gender, male, n(%) | 4146 | 2910 (70.2) | 1171 | 811 (69.3) | 2975 | 2099 (70.6) | 0,411 |
| BMI, kg/m2 | 3866 | 25.8 ± 5.9 | 1171 | 26.1 ± 5.9 | 2695 | 25.6 ± 6.0 | 0.044* |
| COPD GOLD stages, n(%) | 3730 | 1171 | 2559 | ||||
| GOLD I | 745 (20.0) | 241 (20.6) | 504 (19.7) | 0,53 | |||
| GOLD II | 1594 (42.7) | 501 (42.8) | 1093 (42.7) | 0,967 | |||
| GOLD III | 883 (23.7) | 294 (25.1) | 589 (23.0) | 0,163 | |||
| GOLD IV | 508 (13.6) | 135 (11.5) | 373 (14.6) | 0.012* | |||
| VEMS, % predicted | 3730 | 59.4 ± 22.8 | 1171 | 59.9 ± 22.1 | 2559 | 59.2 ± 23.0 | 0,293 |
| CVF, % predicted | 3670 | 85.1 ± 22.7 | 1171 | 87.7 ± 23.4 | 2499 | 83.9 ± 22.2 | < 0.001* |
| Active smoker, n(%) | 3829 | 1321 (34.5) | 1158 | 449 (38.8) | 2671 | 872 (32.6) | < 0.001* |
| Cigarette smoker pack-years | 3614 | 43.3 ± 24.4 | 1132 | 45.6 ± 22.8 | 2482 | 42.3 ± 25.0 | < 0.001* |
| mMRC Score | 3231 | 1.9 ± 1.2 | 1171 | 1.7 ± 1.1 | 2060 | 1.9 ± 1.2 | < 0.001* |
| mMRC Score ≥ 2, n (%) | 3231 | 1839 (56.9) | 1171 | 627 (53.5) | 2060 | 1212 (58.8) | 0.004* |
| HAD Score | 1621 | 12.3 ± 7.2 | 1171 | 12.3 ± 7.1 | 450 | 12.5 ± 7.5 | 0,877 |
| CAT score | 1863 | 16.7 ± 7.7 | 1171 | 16.8 ± 7.7 | 692 | 16.6 ± 7.9 | 0,545 |
| DIRECT score | 1803 | 12.1 ± 7.7 | 1171 | 11.8 ± 7.6 | 632 | 12.6 ± 7.9 | 0,05 |
| Treatment category | 3642 | 1171 | 2471 | ||||
| A | 676 (18.6) | 214 (18.3) | 462 (18.7) | 0,76 | |||
| B | 620 (17.0) | 223 (19.0) | 397 (16.1) | 0.026* | |||
| C | 534 (14.7) | 217 (18.5) | 317 (12.8) | < 0.001* | |||
| D | 498 (13.7) | 132 (11.3) | 366 (14.8) | 0.004* | |||
| E | 1314 (36.1) | 385 (32.9) | 929 (37.6) | 0.006* | |||
| LTOT, n(%) | 4157 | 768 (18.5) | 1171 | 170 (14.5) | 2986 | 598 (20.0) | < 0.001* |
| Long-term NIV, n(%) | 4157 | 246 (5.9) | 1171 | 83 (7.1) | 2986 | 163 (5.5) | 0.045* |
| Long-term CPAP, n(%) | 4157 | 319 (7.7) | 1171 | 68 (5.8) | 2986 | 251 (8.4) | 0.005* |
| Exacerbations last year (≥1 severes or ≥ 2 moderate), n (%) | 3409 | 1251 (36.7) | 1171 | 389 (33.2) | 2238 | 862 (38.5) | 0.002* |
| Cardio-vascular comorbidity | 4157 | 2484 (59.8) | 1171 | 690 (58.9) | 2986 | 1794 (60.1) | 0,494 |
Values were mean ± SD unless otherwise specified. * highlight statistically significant differences
Comparisons by Chi-square analysis (category variables) or T- test (normally distributed continuous variables) or Mann Whitney U test (not normally distributed continuous variables)
A category: no COPD treatment or short-acting bronchodilator(s) (SABA and/or SAMA) only; B category: LABA OR LAMA; C category: LABA+LAMA; D category: LABA OR LAMA + ICS; E category: LABA+LAMA+ICS
HAD hospital anxiety-depression scale, mMRC modified medical research council dyspnea scale, CAT COPD assessment test, DIRECT Disability Related to COPD Tool, LTOT long-term oxygen therapy, NIV non-invasive ventilation, CPAP continuous positive airway pressure